A case of irreversible bradycardia after rituximab therapy for diffuse large B-cell lymphoma
Nway Le Ko Ko1, Nareg Minaskeian1, Hicham Z El Masry1
1Department of Cardiovascular Medicine, Mayo Clinic Arizona, Phoenix, AZ USA.
Abstract:
This is a case of a middle-aged woman with underlying cardiac conduction system with episodes of AV Wenckebach, who subsequently developed significant AV conduction system abnormalities after receiving one standard dose of Rituximab infusion for diffuse large B-cell lymphoma. Rituximab, being a monoclonal antibody against CD-20 antigen, is effective in treatment of B-cell lymphoma but may also cause bradyarrythmias likely due to the calcium ion channel property of CD-20 antigen.
More Related Videos
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
Related Concept Videos
Decreased pulse rate
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with...
Dysrhythmias IV: Characteristics of Bradyarrhythmias
Cardiomyopathy IV: Restrictive Cardiomyopathy
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Cardiomyopathy II: Dilated Cardiomyopathy
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
